The Current Ratio as of November 2024 (TTM) for BioAtla, Inc. (BCAB) is 3.11

According to BioAtla, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.11. This represents a change of -19.76% compared to the average of 3.88 of the last 4 quarters.

BioAtla, Inc. (BCAB) Historical Current Ratio (quarterly & annually)

How has BCAB Current Ratio performed in the past?

The mean historical Current Ratio of BioAtla, Inc. over the last ten years is 5.85. The current 3.11 Current Ratio has changed 5.22% with respect to the historical average. Over the past ten years (40 quarters), BCAB's Current Ratio was at its highest in in the March 2022 quarter at 13.03. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

BioAtla, Inc. (BCAB) Current Ratio by Quarter and Year

Discovering the peaks and valleys of BioAtla, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BioAtla, Inc. (BCAB) Average Current Ratio

How has BCAB Current Ratio performed in the past?

The current Current Ratio of BioAtla, Inc. (BCAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

BioAtla, Inc. (BCAB) Current Ratio vs. Peers

How is BCAB’s Current Ratio compared to its peers?

BioAtla, Inc.’s Current Ratio is less than PMV Pharmaceuticals, Inc. (13.98), less than C4 Therapeutics, Inc. (6.31), less than Nautilus Biotechnology, Inc. (16.65), less than Century Therapeutics, Inc. (10.39), less than Passage Bio, Inc. (5.15), less than Ikena Oncology, Inc. (15.32), less than Olema Pharmaceuticals, Inc. (7.10), less than Aerovate Therapeutics, Inc. (8.78), greater than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (12.75), less than Rezolute, Inc. (13.79), less than AN2 Therapeutics, Inc. (9.75), less than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), less than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Erasca, Inc. (11.00), less than Foghorn Therapeutics Inc. (4.77), less than Shattuck Labs, Inc. (7.96), less than Kymera Therapeutics, Inc. (8.55), less than Nurix Therapeutics, Inc. (5.28),

Build a custom stock screener for BioAtla, Inc. (BCAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioAtla, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioAtla, Inc. (BCAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioAtla, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.